Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. more
Time Frame | XERS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.41% | -2.06% | -0.55% |
1-Month Return | 12.07% | -1.92% | 2.72% |
3-Month Return | 12.07% | -10.4% | 7.66% |
6-Month Return | 52.58% | -4.6% | 10.15% |
1-Year Return | 64.14% | 4.06% | 27.53% |
3-Year Return | 31.58% | 1.94% | 32.31% |
5-Year Return | -58.01% | 36.48% | 89.2% |
10-Year Return | -83.93% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 2.72M | 20.16M | 110.25M | 110.25M | 163.91M | [{"date":"2019-12-31","value":1.66,"profit":true},{"date":"2020-12-31","value":12.3,"profit":true},{"date":"2021-12-31","value":67.26,"profit":true},{"date":"2022-12-31","value":67.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 1.60M | 9.33M | 22.63M | 22.63M | 28.64M | [{"date":"2019-12-31","value":5.6,"profit":true},{"date":"2020-12-31","value":32.56,"profit":true},{"date":"2021-12-31","value":79.02,"profit":true},{"date":"2022-12-31","value":79.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 1.12M | 10.83M | 87.61M | 87.61M | 135.27M | [{"date":"2019-12-31","value":0.83,"profit":true},{"date":"2020-12-31","value":8,"profit":true},{"date":"2021-12-31","value":64.77,"profit":true},{"date":"2022-12-31","value":64.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 41.11% | 53.72% | 79.47% | 79.47% | 82.52% | [{"date":"2019-12-31","value":49.81,"profit":true},{"date":"2020-12-31","value":65.09,"profit":true},{"date":"2021-12-31","value":96.3,"profit":true},{"date":"2022-12-31","value":96.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 123.50M | 94.37M | 169.55M | 169.55M | 168.44M | [{"date":"2019-12-31","value":72.84,"profit":true},{"date":"2020-12-31","value":55.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.34,"profit":true}] |
Operating Income | (122.38M) | (83.55M) | (81.94M) | (81.94M) | (44.01M) | [{"date":"2019-12-31","value":-12238000000,"profit":false},{"date":"2020-12-31","value":-8354600000,"profit":false},{"date":"2021-12-31","value":-8194000000,"profit":false},{"date":"2022-12-31","value":-8194000000,"profit":false},{"date":"2023-12-31","value":-4401000000,"profit":false}] |
Total Non-Operating Income/Expense | (8.01M) | (15.40M) | (14.44M) | (26.89M) | (41.35M) | [{"date":"2019-12-31","value":-800800000,"profit":false},{"date":"2020-12-31","value":-1539900000,"profit":false},{"date":"2021-12-31","value":-1443600000,"profit":false},{"date":"2022-12-31","value":-2689100000,"profit":false},{"date":"2023-12-31","value":-4135200000,"profit":false}] |
Pre-Tax Income | (126.04M) | (91.25M) | (96.08M) | (96.08M) | (63.50M) | [{"date":"2019-12-31","value":-12603800000,"profit":false},{"date":"2020-12-31","value":-9125000000,"profit":false},{"date":"2021-12-31","value":-9608400000,"profit":false},{"date":"2022-12-31","value":-9608400000,"profit":false},{"date":"2023-12-31","value":-6350400000,"profit":false}] |
Income Taxes | (458.00K) | (110.00K) | (1.42M) | (1.42M) | (1.25M) | [{"date":"2019-12-31","value":-45800000,"profit":false},{"date":"2020-12-31","value":-11000000,"profit":false},{"date":"2021-12-31","value":-142400000,"profit":false},{"date":"2022-12-31","value":-142400000,"profit":false},{"date":"2023-12-31","value":-124900000,"profit":false}] |
Income After Taxes | (125.58M) | (91.14M) | (94.66M) | (94.66M) | (62.26M) | [{"date":"2019-12-31","value":-12558000000,"profit":false},{"date":"2020-12-31","value":-9114000000,"profit":false},{"date":"2021-12-31","value":-9466000000,"profit":false},{"date":"2022-12-31","value":-9466000000,"profit":false},{"date":"2023-12-31","value":-6225500000,"profit":false}] |
Income From Continuous Operations | (125.58M) | (91.14M) | (122.72M) | (94.66M) | (62.26M) | [{"date":"2019-12-31","value":-12558000000,"profit":false},{"date":"2020-12-31","value":-9114000000,"profit":false},{"date":"2021-12-31","value":-12272500000,"profit":false},{"date":"2022-12-31","value":-9466000000,"profit":false},{"date":"2023-12-31","value":-6225500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (125.58M) | (91.14M) | (94.66M) | (94.66M) | (62.26M) | [{"date":"2019-12-31","value":-12558000000,"profit":false},{"date":"2020-12-31","value":-9114000000,"profit":false},{"date":"2021-12-31","value":-9466000000,"profit":false},{"date":"2022-12-31","value":-9466000000,"profit":false},{"date":"2023-12-31","value":-6225500000,"profit":false}] |
EPS (Diluted) | (4.80) | (2.28) | (1.52) | (0.70) | (0.45) | [{"date":"2019-12-31","value":-480,"profit":false},{"date":"2020-12-31","value":-228,"profit":false},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-70,"profit":false},{"date":"2023-12-31","value":-45,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
XERS | |
---|---|
Cash Ratio | 0.76 |
Current Ratio | 1.79 |
Quick Ratio | 1.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
XERS | |
---|---|
ROA (LTM) | -8.70% |
ROE (LTM) | -617.16% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
XERS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.09 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
XERS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2.71 |
P/B | 3.34 |
Price/FCF | NM |
EV/R | 3.76 |
EV/Ebitda | NM |
Xeris Pharmaceuticals Inc (XERS) share price today is $3.25
Yes, Indians can buy shares of Xeris Pharmaceuticals Inc (XERS) on Vested. To buy Xeris Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XERS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Xeris Pharmaceuticals Inc (XERS) via the Vested app. You can start investing in Xeris Pharmaceuticals Inc (XERS) with a minimum investment of $1.
You can invest in shares of Xeris Pharmaceuticals Inc (XERS) via Vested in three simple steps:
The 52-week high price of Xeris Pharmaceuticals Inc (XERS) is $3.87. The 52-week low price of Xeris Pharmaceuticals Inc (XERS) is $1.69.
The price-to-earnings (P/E) ratio of Xeris Pharmaceuticals Inc (XERS) is
The price-to-book (P/B) ratio of Xeris Pharmaceuticals Inc (XERS) is 3.34
The dividend yield of Xeris Pharmaceuticals Inc (XERS) is 0.00%
The market capitalization of Xeris Pharmaceuticals Inc (XERS) is $508.37M
The stock symbol (or ticker) of Xeris Pharmaceuticals Inc is XERS